COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Inhibition of Anaphylaxis by Ibrutinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03149315
Recruitment Status : Completed
First Posted : May 11, 2017
Last Update Posted : November 16, 2018
Feinberg School of Medicine, Northwestern University
Information provided by (Responsible Party):
Anne Marie Singh, MD, Ann & Robert H Lurie Children's Hospital of Chicago

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the Results Quality Control (QC) review process. Results information is submitted to by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Completed
Actual Primary Completion Date : November 14, 2018
Actual Study Completion Date : November 14, 2018
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 February 5, 2020
February 18, 2020 Submission with QC Comments
2 February 19, 2020
March 9, 2020 Submission with QC Comments